Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1645
This examiner grants 36% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17422490 | SYSTEMS AND METHODS FOR CULTURING CELLS IN SUSPENSION | Non-Final OA | CORNING INCORPORATED |
| 17433655 | POLYRIBONUCLEOTIDES AND COSMETIC USES THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18456037 | MODIFIED CYANOBACTERIUM, MODIFIED CYANOBACTERIUM PRODUCTION METHOD, AND PROTEIN PRODUCTION METHOD | Non-Final OA | Panasonic Intellectual Property Management Co., Ltd. |
| 17748617 | MODIFIED CYANOBACTERIUM, MODIFIED CYANOBACTERIUM PRODUCTION METHOD, AND PROTEIN PRODUCTION METHOD | Non-Final OA | Panasonic Intellectual Property Management Co., Ltd. |
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17430341 | MODULATION OF REP PROTEIN ACTIVITY IN CLOSED-ENDED DNA (CEDNA) PRODUCTION | Non-Final OA | Generation Bio Co. |
| 17820372 | Rolling Circle Reverse Transcription of Circular RNA | Non-Final OA | New England Biolabs, Inc. |
| 17766003 | EPIGENETIC MODULATION OF GENOMIC TARGETS TO CONTROL EXPRESSION OF PWS-ASSOCIATED GENES | Non-Final OA | Duke University |
| 17278189 | IMPROVED HIGH-THROUGHPUT COMBINATORIAL GENETIC MODIFICATION SYSTEM AND OPTIMIZED CAS9 ENZYME VARIANTS | Final Rejection | The University of Hong Kong |
| 17437504 | CAS9 VARIANTS WITH ENHANCED SPECIFICITY | Non-Final OA | Max-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. |
| 17998603 | BASE EDITING APPROACHES FOR THE TREATMENT OF BETAHEMOGLOBINOPATHIES | Final Rejection | Fondation Imagine |
| 17637058 | COMPOSITIONS AND METHODS FOR IN VIVO GENE EDITING | Non-Final OA | Salk Institute for Biological Studies |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | Non-Final OA | Cancer Research Technology Limited |
| 17797986 | COMPOSITIONS AND METHODS FOR TARGETING, EDITING OR MODIFYING HUMAN GENES | Final Rejection | DANMARKS TEKNISKE UNIVERSITET |
| 17935042 | EFFECTOR PROTEINS AND METHODS OF USE | Non-Final OA | Mammoth Biosciences, Inc. |
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | Final Rejection | BIOVERATIV THERAPEUTICS INC. |
| 17830212 | GENE EDITING SYSTEMS COMPRISING A CRISPR NUCLEASE AND USES THEREOF | Final Rejection | Arbor Biotechnologies, Inc. |
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | Non-Final OA | BioNTech SE |
| 18316828 | CASTRATION RESISTANT PROSTATE CANCER | Non-Final OA | TARGIMMUNE THERAPEUTICS AG |
| 18035871 | CATALYTIC SEQUENCE BASED METHODS OF TREATING OR PREVENTING BACTERIAL INFECTIONS | Non-Final OA | 1E Therapeutics Ltd. |
| 18034821 | METHODS FOR TREATING OPHTHALMOLOGICAL CONDITIONS | Non-Final OA | IVERIC bio, Inc. |
| 18033280 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Non-Final OA | FELDAN BIO INC. |
| 18025446 | TARGETED DEAMINASE AND BASE EDITING USING SAME | Non-Final OA | INSTITUTE FOR BASIC SCIENCE |
| 17636607 | BASE EDITING SYSTEMS FOR ACHIEVING C TO A AND C TO G BASE MUTATION AND APPLICATION THEREOF | Non-Final OA | TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES |
| 17952252 | UBIQUITIN VARIANTS WITH IMPROVED AFFINITY FOR 53BP1 | Non-Final OA | Integrated DNA Technologies, Inc. |
| 17055511 | BACTERIAL VECTORS FOR GENETIC MANIPULATION OF BACTERIA | Non-Final OA | BIOVERSYS AG |
| 17774393 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Non-Final OA | Locus Biosciences, Inc. |
| 17762355 | Methods of Treatment of Neurofibromatosis Type 1 (NF1) and NF-1 Mediated Conditions and Compositions for Use in Such Methods | Final Rejection | Royal Holloway and Bedford New College, |
| 17638610 | COMPOSITIONS AND METHODS FOR CD123 MODIFICATION | Final Rejection | SYZYGYMED INC. |
| 17647480 | NOVEL NUCLEIC ACID MOLECULES AND THEIR USE IN THERAPY | Final Rejection | HEPGENE MEDICAL AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy